Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pauluzzi, S.
Right arrow Articles by Frongillo, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pauluzzi, S.
Right arrow Articles by Frongillo, R. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 431-438
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

Treatment of infections by staphylococci and other Gram-positive bacteria with teicoplanin: an open study

Sergio Pauluzzia, Albano Del Faverob, Francesco Menichettia, Enrico Barattab, Vittoria M. Morettia, Paolo Di Filippoc, Maria B. Pasticcia, Roberto Guerciolinib, Lucio Patoiab and Renato F. Frongilloa

aInstitute of Infectious Diseases, University of Perugia Medical School Perugia, Italy bFirst Institute of Internal Medicine, University of Perugia Medical School Perugia, Italy cOrthopedic Clinic, University of Perugia Medical School Perugia, Italy

Received 28 February 1987;

Teicoplanin, 200–400 mg (3–6 mg/kg) daily iv or im, was used to treat 71 episodes of infection. The average duration of treatment was 22 days. The 64 evaluable episodes comprised 24 skin/soft tissue, 20 osteoarticular, ten urinary tract and one ventriculo-atrial shunt infections; one case of primary bacteraemia, three of endocarditis, two of pneumonia and three of pleural empyema. Fifty-five episodes were treated with teicoplanin monotherapy and nine with teicoplanin in association to other antibiotics. Overall 61% (39/64) of the evaluable infections were cured, 25% (16/64) improved and 14% (9/64) failed. Staphylococcus aureus was the most frequent pathogen, with 46 isolates. Infections by both methicillin-sensitive and resistant Staph. aureus strains showed favourable clinical and microbiological responses to teicoplanin. Side effects were observed in eight of the 64 episodes (12.5%). Bronchospasm was observed in two other cases at the beginning of therapy and the antibiotic administration was discontinued. Teicoplanin is an effective and well tolerated antibiotic for infections by Gram-positive bacteria, and it is effective against methicillin-resistant staphylococci.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
S.-H. Hsiao, C.-M. Chang, J.-C. Tsai, C.-Y. Lin, L.-H. Liao, W.-L. Lin, and T.-J. Wu
Glycopeptide-Induced Neutropenia: Cross-Reactivity Between Vancomycin and Teicoplanin
Ann. Pharmacother., May 1, 2007; 41(5): 891 - 894.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.